CA-NEXON-AMERICA
MapleStory , the iconic free-to-play global MMORPG from Nexon , has today launched Neo: Darkness Ascending, Part One of its summer update, the largest content update to the game in 2021. Neo Part One adds an all new area, Cernium, increases the max level to 300, and offers special limited-time events today, in addition to adding a new Nova Archer job, Kain, on June 23.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005162/en/
First, a new Nova Archer job – the Darkness Chaser, Kain – joins the game on June 23. Kain is a powerful archer, fighting to recover his lost past after discovering that his organization had deceived him. Using the Whispershot, a one-handed weapon, alongside melee weapons from his Weapon Belt, Kain commands an effective and versatile weapons mastery to inflict critical hits on his enemies.
The border between two worlds has disappeared and Cernium, City of the Gods, has reappeared. New area Cernium is now available in-game and brings new challenges and quests to all players. For an added boost, a special power called Sacred Power is now available to aid in the battle against monsters inhabiting the Grandis Continent. Sacred Power is acquired by equipping Sacred Symbols, which can be enhanced to increase Sacred Power as well as main stats.
Starting today, the maximum character level is increased from 275 to 300 and the amount of EXP required to level up between levels 210-250 has been reduced. The update also includes increased EXP rewards for Arcane River quests, and modifies the character death penalty to a decreased drop rate percentage instead of overall experience lost.
Part One of the Neo Update also brings the new Neo Castle event to MapleStory . Neo Castle, an area shrouded in mystery, was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events with the following features and shops available now:
- Neo Stone Shop : Players can exchange Neo Stones for a variety of improvements that can be used to enhance items and boost character growth
- Neo Gem Shop : Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop : Neo Cores can be collected by battling bosses and can be used to purchase a variety of rare items
- Neo Meso Shop : The Meso shop is stocked full of powerful items that can be purchased using Mesos
The Neo Update also includes the following updates and features:
Burning World and Tera Burning
Burning World and Tera Burning events return to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon.
The Better Maple Project brings a host of new improvements for overall improved gameplay including:
- The V Matrix has been improved for easier use
- Boss Battles have been improved and a new boss entry system has been added, allowing players to move to the waiting area immediately from the current channel simply by selecting the boss, difficulty and pressing “GO”
- Skill Tooltips have been widened for better legibility and understanding of skill descriptions
- Equipped item functionality has been improved, allowing players the ability to compare equipped items with other items linked in chat
- The Clean Slate Scroll has been updated, and while in possession, is changed to a Pure Clean Slate Scroll to protect the item from being destroyed when it fails
- A Notification has been added to alert players when Safeguard is automatically disabled during Star Force enhancement
- Meso Market trades that are in progress for other characters in the same world have been updated and can be viewed in addition to canceling or receiving trades
- The Meso Market’s daily listing limit has been increased to 20
- Maplers can now purchase Mu Gong's Soul Shard from the Mu Lung Dojo Point Shop
To learn more about MapleStory , please visit http://maplestory.nexon.net
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
